Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state

Summary

Paediatric obesity, like adulthood obesity, is associated with an increase of fibrinolysis inhibitors. No study, however, has evaluated the impact of these changes on plasma fibrinolytic capacity. We investigated plasma fibrinolysis and the role therein of the fibrinolytic changes associated with obesity in 59 obese children (body mass index > 95^th percentile) and 40 matched controls. Fibrinolysis was investigated by measuring 1) the plasma levels of relevant fibrinolytic factors; 2) the in vitro fibrinolytic capacity under different conditions, using a microplate plasma clot lysis assay; 3) the circulating levels of markers of clotting and fibrinolysis activation. Plasminogen activator inhibitor 1 (PAI-1), total thrombin activatable fibrinolysis inhibitor (TAFI) and fibrinogen levels were higher in obese children as compared to controls (p<0.01). Plasma clots from obese children lysed significantly slower than control clots when exposed to exogenous plasminogen activator, indicating a greater resistance to fibrinolysis. By the use of a selective inhibitor of activated TAFI and by regression analyses we found that fibrinolysis resistance in obese samples was attributable to PAI-1 increase and to enhanced TAFI activation. The ratio between the circulating levels of D-dimer and thrombin-antithrombin complex, a marker of in vivo fibri-nolysis, was significantly lower in obese children, suggesting a reduced fibrinolytic efficiency. These data indicate that paediatric obesity is associated with a hypofibrinolytic state which might contribute to the increased thrombotic risk associated with this condition.

Keywords

Fibrinolytic capacity - PAI-1 - TAFI - thrombin - thrombotic risk

• References

• 1 Cali AM, Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab 2008; 93 (Suppl. 01) S31-36.
• 2 Daniels SR. The consequences of childhood overweight and obesity. Future Child 2006; 16: 47-67.
• 3 Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10: 554-563.
• 4 Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 03: 85-101.
• 5 Ferguson MA, Gutin B, Owens S. et al. Fat distribution and hemostatic measures in obese children. Am J Clin Nutr 1998; 67: 1136-1140.
• 6 Valle M, Gascón F, Martos R. et al. Infantile obesity: a situation of atherothrombotic risk?. Metabolism 2000; 49: 672-675.
• 7 Estellés A, Dalmau J, Falcó C. et al. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-652.
• 8 Balagopal P, George D, Sweeten S. et al. Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children. J Thromb Haemost 2008; 06: 1296-1303.
• 9 Mauras N, Delgiorno C, Kollman C. et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010; 95: 1060-1068.
• 10 Aubert H, Frère C, Aillaud MF. et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 01: 791-797.
• 11 Guven GS, Kiliçaslan A, Oz SG. et al. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Clin Appl Thromb Hemost 2006; 12: 364-368.
• 12 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
• 13 Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26: 2445-2453.
• 14 Cacciari E, Balsamo A, Palareti G. et al. Haemorheologic and fibrinolytic evaluation in obese children and adolescents. Eur J Pediatr 1988; 147: 381-384.
• 15 Cacciari E, Coccheri S, Bergamaschi R. et al. Hemostatic balance alterations in obese children. Acta Paediatr Scand 1982; 71: 479-484.
• 16 Cole TJ, Bellizzi MC, Flegal KM. et al. Establishing a standard definition for child overweight and obesity worldwide: International survey. Brit Med J 2000; 320: 1240-1243.
• 17 Giordano P, Del Vecchio GC, Cecinati V. et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr 2011; 170: 845-850.
• 18 Colucci M, Binetti BM, Tripodi A. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-2161.
• 19 Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 01: 1566-1574.
• 20 Bolliger D, Szlam F, Molinaro RJ. et al. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102: 793-799.
• 21 Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
• 22 Tosetto A, Missiaglia E, Gatto E. et al. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Thromb Haemost 1997; 78: 859-863.
• 23 Lowe GD, Rumley A, Woodward M. et al. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-924.
• 24 Landin K, Stigendal L, Eriksson E. et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048.
• 25 Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-1364.
• 26 Lisman T, Leebek FWG, Mosnier LO. et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
• 27 Rijken DC, Hoegee-De Nobel E, Jie AFH. et al. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008; 06: 151-157.
• 28 Lisman T, de Groot PG, Meijers JC. et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
• 29 Leurs J, Wissing BM, Nerme V. et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-271.
• 30 Ammollo CT, Semeraro F, Incampo F. et al. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 08: 790-798.
• 31 Bajzar L, Kalafatis M, Simioni P. et al. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V^Leiden . J Biol Chem 1996; 271: 22949-22952.
• 32 Colucci M, Simioni P, Piro D. et al. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia. Haematologica 2003; 88: 1383-1389.
• 33 Binetti BM, Rotunno C, Tripodi A. et al. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis. Thromb Haemost 2006; 95: 606-611.
• 34 Solá E, Vayá A, Villa P. et al. Obesity and activated protein C resistance. Pathophysiol Haemost Thromb 2008; 36: 64-68.
• 35 Broze Jr GJ. Thrombin-dependent inhibition of fibrinolysis. Curr Opin Hematol 1996; 03: 390-394.
• 36 Von dem Borne PA, Bajzar L, Meijers JC. et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-2327.
• 37 Pomp ER, le Cessie S, Rosendaal FR. et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
• 38 Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37: 903-907.
• 39 Vu LT, Nobuhara KK, Lee H. et al. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg 2008; 43: 1095-1099.
• 40 Rana AR, Michalsky MP, Teich S. et al. Childhood obesity: a risk factor for injuries observed at a level-1 trauma center. J Pediatr Surg 2009; 44: 1601-1605.
• 41 Guimarães AH, de Bruijne EL, Lisman T. et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-120.
• 42 Pankiw-Bembenek O, Zalewski J, Goralczyk T. et al. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012; 107: 513-520.